James W. Crow
United States of America
Dr. Crow has a long and distinguished career in the pharmaceutical industry, spanning nearly 35 years. Jim spent many years at Burroughs Wellcome, where he held various positions including Section Head/Associate Medical Director. In addition to his management duties at Burroughs Wellcome, he lead numerous cross-divisional, international projects from preclinical, Pre-IND, through the Clinical Phases of Development and subsequent regulatory review process. One highlight of tenure was his leadership of the epoprostenol program, a drug targeting an unmet medical need. Jim successfully led this complex development, and epoprostenol (Flolan) became the first treatment approved to treat severely ill patients with Pulmonary Arterial Hypertension. This breakthrough medicine saved and extended many lives.